Background {#Sec1}
==========

Sickle cell disease (SCD) is a hereditary disorder of hemoglobin (Hb) characterized by inheritance of two abnormal Hb genes, at least one of which is responsible for the production of HbS. The most common clinical phenotype is the homozygote (Hb SS), also known as sickle cell anemia. It is commonly characterized by chronic hemolytic anemia and recurrent vaso-occlusion which is responsible for the painful crises that characterize the disease. In Africa and Asia, SCD occurs in areas where malaria is endemic \[[@CR1]\]. Malaria and bacterial infections such as pneumococcal infections result in morbidity and mortality of SCD patients in Sub-Saharan Africa (SSA) \[[@CR2], [@CR3]\]. Malaria contributes not only to mortality, but also to anemia and SCD crises \[[@CR2]\].

In SSA, SCD is a disease of public health concern. In 2010, the region had nearly 80 % of the projected 306,000 newborns with SCD worldwide \[[@CR4]\]. Mortality estimates among SCD children in SSA range from 50--90 % before age 5 \[[@CR5]\]. In contrast, life-expectancy for SCD patients has improved in western countries and most patients live to their 40s and 50s \[[@CR6]\]. In those countries, newborn screening programs were introduced incorporating testing newborns for SCD plus interventions (penicillin prophylaxis and pneumococcal vaccination) to prevent bacterial infections among diagnosed cases. Although newborn screening was shown to be cost-effective among African American infants \[[@CR7]\], this approach has not been widely adopted in SSA. In SSA, malaria is endemic and newborn screening programs require an additional component of malaria prevention. Evidence from prospective studies in Benin and Angola indicate that a package of prophylactic interventions can reduce the infant and under-5 mortality among newborns with SCD to levels similar to those of the general population \[[@CR8], [@CR9]\].

Despite the high SCD burden in SSA, newborn screening and prophylactic intervention (NSPI) programs have not been widely implemented due to concerns of affordability, costs, operational challenges and competing priorities. This analysis assesses the cost-effectiveness of a NSPI program in SSA.

Methods {#Sec2}
=======

A decision analytic model was developed to compare NSPI for SCD relative to no screening, from the perspective of the national health systems in 47 countries in SSA. The model structure was adapted from a previous cost-effectiveness analysis of newborn screening for SCD in the United States \[[@CR7]\], and based on a lifetime Markov state transition cohort with annual cycle lengths and the standard half-cycle correction. A graphical representation of the model structure is displayed in Fig. [1](#Fig1){ref-type="fig"}. Infants identified to have SCD could either remain alive with SCD, or progress to the terminal steady state of death. In each annual cycle, infants accrued life-years, adjusted for disability. Infants in the NSPI arm of the model consumed health care resources in each cycle. The resource use associated with no screening was assumed to be zero. The common model structure was populated with country-specific model inputs, in order to yield 47 model results.Fig. 1Markov model graphic

In the model, every infant was tested at birth for SCD using isoelectric focusing (IEF). Infants with a positive confirmatory test result would initiate an array of prophylactic therapies to reduce the risk of malaria and other infections. Unscreened infants were assumed to remain undiagnosed and untreated. For these infants, the annual probability of mortality was stratified between infants born in rural versus urban areas because prior studies have suggested that infection rates and access to healthcare services could differ between rural and urban areas \[[@CR5]\]. A third option of delaying screening upon the onset of symptoms was not included, because SCD-associated mortality may occur before the onset of symptoms, particularly in rural areas. In the intervention arm, the annual probability of mortality among treated infants was stratified for four separate age categories: less than 5 years, 6 years to 20 years, 21 years to 30 years and 31 years and older. For the age categories below 30 years, mortality rates were obtained from a Tanzanian hospital-based cohort and generalized to the other 46 countries included in the model \[[@CR10]\]. Beyond 30 years of age, a multiplier was applied to the annual probability of mortality in the general population. All future costs and benefits were discounted at 3 % annually \[[@CR11]\]. Calculations were performed using TreeAge Pro 2014, R1.0 (Treeage Software Inc., Williamstown, MA, USA).

Formal ethics approval and consent to participate was not required in this retrospective analysis of observational data.

Clinical and epidemiologic inputs {#Sec3}
---------------------------------

General model and country-specific model inputs are displayed in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}, respectively. The incidence of SCD in newborns was based on published estimates \[[@CR4]\]. To generate an estimate of the local incidence rate, the authors reported median annual number of infants born with sickle cell disease for each of the 47 countries of interest and compared these estimates to the annual number of live births in the 2010 United Nations national population estimates \[[@CR12]\]. IEF was assumed to have 100 % sensitivity and specificity \[[@CR13]\].Table 1General model inputsBasecaseRangeDistributionReferenceAccuracy of Screening Method Sensitivity, Isoelectric Focusing100.0 %99.9 %100.0 %Exponential\[[@CR13]\] Specificity, Isoelectric Focusing100.0 %99.9 %100.0 %Exponential\[[@CR13]\]Annual Mortality Risk, Untreated Rural37.0 %13.3 %64.8 %Beta\[[@CR5]\] Urban13.0 %4.9 %24.4 %Beta\[[@CR5]\]Annual Mortality Risk, Treated \<= 5 years7.3 %4.1 %10.5 %Normal\[[@CR10]\] 6--20 years1.4 %1.0 %1.8 %Normal\[[@CR10]\] 21--30 years1.8 %1.1 %2.5 %Normal\[[@CR10]\] \>31 years, general population multiplier4.53.06.0NormalOwn calculationDisability Weight0.040.020.06Beta\[[@CR16]\]Costs - Screening Isoelectric Focusing -- fixed cost per sample\$0.044\$0.022\$0.088Log-normal\[[@CR17]\] Isoelectric Focusing -- all variable costs\$9.90\$4.45\$18.80Log-normalUNHL^a^Annual costs - treatment Pneumoccocal Vaccine, year 1 only\$80.64\$40.32\$120.96Log-normalAKTH^b^ Mosquito Net, annual for life\$10.00\$5.00\$15.00Log-normal\[[@CR18]\] Proguanil 100 mg, daily for years 1--15\$17.48\$8.74\$26.22Log-normal\[[@CR19]\] Proguanil 200 mg, daily for years \>15\$34.97\$17.49\$52.46Log-normal\[[@CR19]\] Folic Acid 5 mg, daily for life\$0.77\$0.39\$1.16Log-normal\[[@CR19]\] Penicillin 125 mg, twice daily for years 1--5\$29.93\$14.97\$44.90Log-normal\[[@CR19]\] Penicillin 250 mg, twice daily for years 6--10\$50.37\$25.19\$75.56Log-normal\[[@CR19]\] Discount Rate3.0 %0.0 %6.0 %n/A\[[@CR11]\]^a^Average cost per isoelectric focusing obtained from Ugandan National Health Laboratory (UNHL) in Kampala, Uganda^b^Local pharmacy costs obtained from Aminu Kano Teaching Hospital (AKTH), Kano, NigeriaTable 2Country-specific model inputsCountry nameLive births, 2010 \[[@CR12]\]Median incidence of SCD, 2010 \[[@CR4]\]Incidence rate (\[[@CR4]\] divided by \[[@CR12]\])Percentage of population living in rural areas \[[@CR14]\]GDP per capita (US\$) 2014 \[[@CR26]\]Angola758,0008,3641.10 %40.80 %\$5,900Benin353,0004,5431.29 %55.10 %\$890Botswana45,00040.01 %38.30 %\$7,240Burkina Faso689,0003,1240.45 %73.50 %\$700Burundi284,0008890.31 %89.10 %\$270Cameroon697,0006,9150.99 %47.90 %\$1,350Cape Verde10,000180.18 %37.40 %\$3,450Central African Republic155,0009760.63 %60.90 %\$320Chad499,0002,0450.41 %78.20 %\$980Comoros25,000250.10 %72.00 %\$790Côte d'Ivoire712,0003,5670.50 %48.70 %\$1,450Congo-Brazzaville130,0001,5601.20 %36.30 %\$2,720DR Congo2,856,00038,2171.34 %65.70 %\$380Djibouti25,00000.00 %22.90 %\$1,810Equatorial Guinea25,0003851.54 %60.50 %\$10,210Eritrea179,00090.01 %78.70 %\$680Ethiopia2,550,0001370.01 %83.00 %\$550Gabon41,0008642.11 %13.80 %\$9,720Gambia65,0004180.64 %42.70 %\$500Ghana737,0005,4740.74 %48.10 %\$1,760Guinea388,0005,2321.35 %64.60 %\$470Guinea-Bissau62,0001920.31 %56.10 %\$550Kenya1,507,0004,4750.30 %76.00 %\$1,290Lesotho56,00000.00 %72.40 %\$1,330Liberia154,0005620.36 %51.80 %\$370Madagascar697,0003,3790.48 %67.40 %\$440Malawi698,0001,6880.24 %84.30 %\$250Mali601,0002,7010.45 %65.10 %\$650Mauritania110,0004330.39 %58.50 %\$1,270Mauritius16,00000.00 %58.20 %\$9,3630Mozambique850,0001,6450.19 %68.80 %\$600Namibia56,000300.05 %61.60 %\$5,630Niger758,0004,9650.66 %82.20 %\$410Nigeria6,219,00085,1861.37 %50.40 %\$2,970Rwanda417,0006010.14 %80.90 %\$700Sao Tome and Principe5,000410.82 %37.30 %\$1,670Senegal462,0002,5350.55 %57.50 %\$1,050Sierra Leone213,0002,8381.33 %60.80 %\$700Somalia402,00013\<0.01 %62.30 %\$107^30^South Africa1,036,000730.01 %38.00 %\$6,800Sudan1,378,0004,5670.33 %66.80 %\$1,710Swaziland34,00040.01 %78.80 %\$3,550Tanzania1,846,00011,0220.60 %73.30 %\$920Togo210,0002,1751.04 %62.00 %\$570Uganda1,484,00010,1430.68 %84.40 %\$670Zambia616,0005,6520.92 %60.80 %\$1,680Zimbabwe363,0004830.13 %61.40 %\$840Sum31,473,000228,1690.72 %N/AN/A

The under-5 probability of mortality in the unscreened arm of the model was 50 % for infants born in urban areas and 90 % for infants born in rural areas \[[@CR5]\]. These under-5 mortality rates were converted into annual mortality rates of 13 % in urban and 37 % in rural areas, respectively, and carried forward in all future cycles beyond the age of 5. The country-specific proportions of rural and urban populations was obtained from a 2011 United Nations report \[[@CR14]\]. For screened and treated infants, the observed annual probability of mortality from the Tanzanian cohort was applied to all 47 countries in our model for the age categories of under 5 (7.3 % per year), 6 to 20 (1.4 % per year), and 21 to 30 (1.8 % per year) \[[@CR10]\]. Beyond 30 years of age, we applied a multiplier of 4.5 to the country-specific probability of mortality in the general population \[[@CR15]\] to reflect for the higher mortality risk associated with SCD. The multiplier was derived by comparing the mortality risk in the Tanzanian cohort for six 5-year age increments of 0--5, 6--10, 11--15, 16--20, 21--25, and 26--30 years of 31.5 %, 6.8 %, 6.8 %, 6.8 %, 8.7 % and 8.7 % \[[@CR10]\], to those in the general population in Tanzania of 5.4 %, 1.6 %, 1.3 %, 1.6 %, 2.1 %, and 2.9 % \[[@CR15]\], and taking average ratio of these six age-pairs. Finally, a disability weight of 0.04 was used to account for the disability burden associated with the presence of SCD, based on an assessment of the impact of anemia without painful crises or other complications \[[@CR16]\].

Cost inputs {#Sec4}
-----------

All costs were expressed in 2014 US\$. The cost per IEF was assumed to consist of the cost of equipment, materials and the labor cost to perform the analysis. We assumed all isoelectric focusing would be conducted using the GE Healthcare Multiphor II Electrophoresis system \# 18-1018-06, which is available at a cost of \$4,210 per unit \[[@CR17]\]. The fixed cost was converted into an average cost per screening on the basis of a useful life of 5 years and a maximum number of screenings per day of 80, e.g. 19,200 per year at full capacity. The daily limit of 80 was chosen, because each machine can run up to 80 samples simultaneously. This translates into an average cost per sample of US\$ 0.044 at full utilization. We assumed that the quantity of IEF systems must be represented by a whole number and countries with fewer than 19,200 live births per year would still need to purchase one analyzer with the fixed cost of the analyzer spread out over fewer tests.

The variable cost per screening was estimated at \$9.90 per test, which was based on an internal analysis of cost data at the Uganda National Health Laboratories, Ministry of Health Kampala, Uganda. This cost estimate accounts for the reagents used in the testing process (\$1.80 per sample), collection materials, which included a dried blood spot kit, gloves, cotton and water (\$1.60 per sample), the cost of overhead, which included professional salaries as well as the rent of the testing facility (\$5.00 per sample) and the transport of the sample to the centralized testing facility in Kampala, Uganda by means of the postal system as well as the communication of test results back to the local testing facilities (\$1.50 per sample). Due to the possibility of sample contamination, this process would be repeated in the case of a positive screening result.

Newborns with a positive confirmatory IEF result would be initiated on interventions to reduce the mortality risk from malaria and other infections. The interventions include pneumococcal vaccination during the first year of life using a three-injection regimen at a cost of US\$ 26.88 per injection (US\$ 80.64 total) based on local pharmacy costs obtained from Aminu Kano Teaching Hospital, Kano, Nigeria. For malaria prevention, an insecticide-treated mosquito bed net would be provided and assumed to be replaced annually at a unit cost of US\$ 10.00 \[[@CR18]\], lifetime prophylactic antimalarial therapy with proguanil 100 mg at a cost of US\$ 0.0479 per day (US\$ 17.48 per year) for children age 0--15 years and proguanil 200 mg at a cost of US\$ 0.0958 per day (US\$ 34.97 per year) for young adults age 16 and older \[[@CR19]\], lifetime supplementation with folic acid 5 mg at a cost of US\$ 0.0026 per day (US\$ 0.95 per year) \[[@CR19]\], prophylactic penicillin V 125 mg (5 ml) twice daily at a cost of US\$ 0.082 per day (US\$ 29.93 per year) for children age 0--5 and prophylactic penicillin V 250 mg (5 ml) twice daily at a cost of US\$ 0.138 per day (US\$ 50.37 per year) for children age 5--10 \[[@CR19]\].

Scenario and sensitivity analyses {#Sec5}
---------------------------------

To test the robustness of model results, select inputs were varied in one-way sensitivity analyses for countries where newborn screening for SCD was found to be cost-effective at baseline. In addition, the incidence estimates for the countries included in our model may have been at least partially based on childhood or adult testing, not necessarily newborn screening. As a result, the true incidence rate may be higher than reported. We therefore tested the impact of a doubling in the incidence rate in scenario analysis \#1. In the same spirit, it is possible that the SCD related mortality rate may also be underreported and we have assessed the impact of a doubling in the mortality rate in scenario analyses \#2. Finally, probabilistic sensitivity analyses (PSA) were performed by running 10,000 iterations of the model, while randomly selecting the values for 10 key model inputs from a probability distribution that was defined for each of the parameters displayed in Table [1](#Tab1){ref-type="table"}. This process enabled us to estimate the 95 % confidence interval around the 47 base case incremental cost effectiveness ratio (ICER) estimates, and also the probability that NSPI is cost-effective in each country.

Results {#Sec6}
=======

The annual number of infants born with SCD in the 47 countries in SSA is estimated at 228,169. The annual incidence is unevenly distributed, with estimates ranging from 0 cases in Djibouti, Lesotho, and Mauritius, to 38,217 and 85,186 in Democratic Republic of Congo (DR Congo) and Nigeria, respectively.

Mean life expectancy of unscreened newborns in rural and urban areas across SSA was estimated at 1.7 years and 6.7 years, respectively. All country-specific base case model outputs are displayed in Table [3](#Tab3){ref-type="table"}. The life expectancy of screened and treated infants ranged from 24.2 years in the Central African Republic to 32.4 years in Cape Verde (mean 27.0 years). The increase in life expectancy associated with NSPI relative to no treatment translates into 2,414,612 disability-adjusted life years (DALYs) that could be averted across all countries. Importantly, DALY estimates from DR Congo and Nigeria alone account for more than 50 % of DALYs that could be averted in this analysis.Table 3Model resultsCountry nameDALYs avertedTotal costsIncremental cost-effectiveness ration (95 % CI)Probability that screening is highly cost-effectiveScenario 1: double SCD incidence rateScenario 2: double mortality rateAngola82,167\$14,874,250\$181 (\$115--\$710)99.01 %\$137\$212Benin49,138\$7,596,778\$154 (\$120--\$391)99.53 %\$120\$178Botswana51\$451,506\$8,853 (\$4 k--\$73 k)^b^16.92 %\$5,273\$12,990Burkina Faso34,415\$9,652,203\$280 (\$197--\$497)99.53 %\$177\$318Burundi10,309\$3,607,194\$350 (\$241--\$607)^b^10.78 %\$214\$408Cameroon69,142\$12,962,308\$187 (\$148--\$855)98.56 %\$139\$219Cape Verde196\$116,771\$596 (\$363--\$2,220)98.17 %\$342\$723Central African Republic9,967\$2,377,372\$239 (\$164--\$584)73.16 %\$163\$281Chad22,655\$6,738,454\$297 (\$199--\$601)99.90 %\$190\$348Comoros285\$271,711\$953 (\$367--\$12,296)^b^31.22 %\$517\$1,139Côte d'Ivoire35,386\$10,169,638\$287 (\$190--\$925)98.36 %\$189\$343Congo-Brazzaville15,353\$2,674,621\$174 (\$108--\$683)98.37 %\$134\$204DR Congo414,120\$62,013,889\$150 (\$105--\$298)99.25 %\$117\$171Djibouti0\$249,184n/A^a^0.00 %n/A^a^n/A^a^Equatorial Guinea4,060\$586,080\$144 (\$98--\$323)99.97 %\$115\$165Eritrea139\$1,788,594\$12,852 (\$3 K--\$125 k)^b^0.00 %\$4,368\$14,435Ethiopia2,198\$25,480,760\$11,591 (\$3--\$113 k)^b^0.00 %\$4,267\$13,283Gabon7,827\$1,175,675\$150 (\$103--\$989)95.54 %\$126\$177Gambia4,277\$1,021,570\$239 (\$160--\$770)93.14 %\$164\$283Ghana57,781\$12,272,350\$212 (\$144--\$635)99.28 %\$150\$249Guinea57,696\$8,528,250\$148 (\$100--\$320)99.44 %\$116\$169Guinea-Bissau2,021\$786,453\$389 (\$238--\$1,150)69.87 %\$239\$466Kenya51,539\$18,968,262\$368 (\$245--\$749)99.26 %\$225\$435Lesotho0\$556,926n/A^a^0.00 %n/A^a^n/A^a^Liberia5,914\$2,037,429\$345 (\$219--\$1,00755.39 %\$215\$410Madagascar37,917\$9,988,026\$263 (\$185--\$523)93.73 %\$172\$307Malawi19,335\$8,411,580\$435 (\$245--\$1,294)^b^4.89 %\$258\$513Mali29,990\$8,394,677\$280 (\$190--\$616)98.29 %\$182\$329Mauritania4,774\$1,488,728\$312 (\$173--\$1,228)95.98 %\$198\$368Mauritius0\$159,242n/A^a^0.00 %n/A^a^n/A^a^Mozambique15,895\$9,851,847\$620 (\$348--\$1,911)^b^32.57 %\$350\$735Namibia308\$583,765\$1,895 (\$810--\$12,129)88.26 %\$994\$2,307Niger59,276\$12,017,462\$203 (\$155--\$758)78.01 %\$141\$234Nigeria867,551\$136,436,100\$157 (\$118--\$630)99.39 %\$123\$182Rwanda6,922\$4,690,792\$678 (\$443--\$4,102)11.41 %\$123\$191Sao Tome and Principe428\$87,930\$205 (\$116--\$4,875)88.64 %\$148\$241Senegal28,136\$6,901,261\$245 (\$190--\$1,091)97.31 %\$165\$288Sierra Leone29,522\$4,580,943\$155 (\$111--\$622)98.10 %\$121\$178Somalia121\$4,008,936\$33,242 (\$21 k--\$190 k)^b^0.00 %\$15,585\$37,835South Africa932\$10,364,811\$11,116 (\$7 k--\$93 k)^b^2.06 %\$5,354\$13,209Sudan51,262\$17,825,373\$348 (\$260--\$1,603)97.98 %\$215\$410Swaziland37\$341,676\$9,136 (\$3 k--\$741 k)^b^1.42 %\$4,729\$11,296Tanzania123,313\$28,082,629\$228 (\$188--\$834)99.98 %\$155\$265Togo23,646\$4,018,804\$170 (\$134--\$600)96.11 %\$128\$196Uganda114,565\$23,587,765\$206 (\$162--\$712)96.65 %\$143\$237Zambia59,074\$11,031,575\$187 (\$147--\$704)99.71 %\$137\$217Zimbabwe4,973\$4,030,324\$810 (\$520--\$5,827)16.35 %\$450\$981Sum/Average2,414,612\$513,842,475\$213n/An/An/A^a^Not applicable (n/A). The ICER is not defined if the number of DALYs averted in the denominator is equal to zero. For purposes of interpretation, the cost-effectiveness ratios in these three cases are approaching infinity, thus, newborn screening for SCD would not be considered cost-effective^b^Denotes ICERs that exceed the cost-effectiveness threshold of a cost per DALY averted of less than one time per capita income as per WHO guidelines \[[@CR11]\], thus, newborn screening for sickle cell disease would not be considered highly cost-effective

The cost of universal newborn screening using IEF in all 47 countries is estimated at US\$312 million per year. Lifetime treatment cost of the prevention package (mean, range) was US\$876 (US\$828-US\$930). The sum cost of a universal NSPI program and the net present value of lifetime treatment costs were US\$514 million per year. Most costs would be borne by Nigeria (approximately US\$136 million) and DR Congo (approximately US\$62 million), but for 34 other countries, the budget impact would still exceed US\$1 million per year.

The incremental cost-effectiveness ratios and corresponding 95 % confidence intervals of NSPI in the 47 countries are displayed in Table [3](#Tab3){ref-type="table"} and, for the subset of 34 countries where screening is cost-effective in the base case, in Fig. [2](#Fig2){ref-type="fig"}. The cost per DALY averted ranges from US\$144 (95 % CI: \$98-\$323) in Equatorial Guinea to an ICER approaching infinity in the three countries that report zero burden of SCD and where no DALYs are therefore expected to be averted. The population-weighted average cost per DALY averted for all 47 countries is US\$213. Among 34 countries with a cost per DALY averted below one time per capita gross domestic product (GDP), the cost per DALY averted is US\$190.Fig. 2Country ICERs^a^ by incidence rate and DALYs that could be averted^b^. ^a^Only countries are shown where screening for SCD was below US1000/DALY averted. ^b^The circle size represents the number of DALYs that could potentially be averted by routine screening and subsequent treatment of all newborns for SCD

Results from scenario and sensitivity analyses {#Sec7}
----------------------------------------------

Results from our two scenario analyses are displayed in Table [3](#Tab3){ref-type="table"}, columns 6 and 7. The ICER estimates decreased in scenario \#1 and increased in scenario \#2 relative to basecase results, but the absolute impact of either one of these two inputs was relatively small for most of the countries in our panel. In the case of six countries, Botswana, Burundi, Comoros, Malawi, Mozambique, and South Africa, the ICER exceeded per capita GDP in the basecase, but would fall below this threshold if the incidence rate were to double. Table [4](#Tab4){ref-type="table"} displays the results from one-way sensitivity analyses. For simplicity, only the high end of the sensitivity range is included and only for countries where the base case estimate indicated that newborn screening for SCD was cost-effective. Generally, the model results proved robust to one-way variations in model parameters. In addition, probabilistic sensitivity analyses suggest that the model results are generally robust to simultaneous variation of all model parameters, as the 95 % CI associated with the ICERs fall below the relevant cost-effectiveness thresholds (Table [3](#Tab3){ref-type="table"}). The probability that the intervention was indeed cost effective with ICER estimates below commonly accepted thresholds generally exceeds 95 % or even 99 %. However, for 10 countries, fewer than 95 % of the iterations fall below the relevant threshold.Table 4Results of 1-way sensitivity analyses^a^SCD incidence-50 %Discount rate 6 %Cost of IEF screening \$15Probability survival Urban areas 95 %/year100 % of population in Urban areasProbability survival rural areas 75 %/yearIEF specificity 99.9 %Disability weight of 0.06IEF sensitivity 99.9 %Angola\$267\$275\$290\$230\$216\$191\$186\$188\$183Benin\$228\$225\$193\$210\$193\$165\$159\$161\$156Burkina Faso\$468\$415\$372\$319\$359\$294\$286\$280\$274Cameroon\$312\$275\$240\$279\$230\$199\$196\$193\$189Cape Verde\$1,107\$1,027\$853\$926\$684\$619\$633\$609\$597Central African Republic\$395\$351\$319\$315\$309\$257\$250\$246\$241Chad\$519\$444\$410\$405\$341\$323\$312\$305\$299Côte d'Ivoire\$490\$437\$391\$425\$354\$305\$302\$296\$290Congo-Brazzaville\$260\$259\$219\$293\$203\$183\$181\$180\$175DR Congo\$220\$212\$187\$195\$188\$162\$156\$155\$152Equatorial Guinea\$208\$203\$177\$186\$190\$156\$150\$149\$146Gabon\$204\$222\$178\$369\$161\$154\$154\$155\$152Gambia\$392\$369\$317\$367\$284\$251\$250\$245\$240Ghana\$341\$324\$278\$306\$257\$224\$222\$218\$214Guinea\$216\$211\$184\$191\$186\$159\$154\$152\$149Guinea-Bissau\$717\$610\$547\$489\$528\$415\$411\$400\$392Kenya\$663\$570\$519\$493\$427\$399\$391\$379\$371Liberia\$605\$544\$477\$479\$421\$364\$363\$353\$346Madagascar\$447\$404\$357\$321\$339\$282\$277\$269\$264Mali\$482\$431\$383\$360\$350\$301\$295\$288\$282Mauritania\$531\$491\$429\$388\$406\$331\$328\$319\$313Namibia\$3,729\$3,128\$2,825\$2,409\$2,433\$2,034\$2,027\$1,946\$1,908Niger\$332\$301\$269\$276\$226\$221\$213\$209\$205Nigeria\$230\$226\$196\$227\$195\$168\$163\$162\$159Rwanda\$1,279\$1,080\$982\$908\$753\$731\$720\$693\$679Sao Tome and Principe\$324\$319\$328\$264\$238\$214\$214\$211\$206Senegal\$484\$380\$330\$306\$324\$261\$258\$252\$247Sierra Leone\$194\$219\$200\$229\$204\$167\$160\$161\$157Sudan\$617\$544\$484\$447\$426\$372\$367\$356\$349Tanzania\$230\$218\$193\$205\$182\$167\$160\$158\$155Togo\$162\$175\$150\$172\$163\$136\$130\$130\$128Uganda\$337\$297\$273\$286\$227\$225\$216\$212\$207Zambia\$293\$271\$242\$241\$246\$201\$196\$193\$189Zimbabwe\$1,545\$1,287\$1,184\$1,041\$1,054\$869\$863\$832\$816^a^This table only displays results for those countries where NSPI was cost-effective in the basecase

Discussion {#Sec8}
==========

To our knowledge, this is the first study to systematically evaluate the cost-effectiveness of NSPI programs across most countries in SSA. Based on the commonly accepted threshold of less than one time per capita GDP to assess a highly cost-effective intervention \[[@CR11]\], we conclude that NSPI provides excellent value per dollar spent in the settings of many, but not all countries in SSA. We propose to classify countries into three distinct categories: In 24 countries, NSPI is almost certainly cost-effective; in 13 countries, NSPI is either unlikely to be, or is certainly not cost-effective; and in 10 countries, NSPI is probably cost-effective, but the findings are subject to varying degrees of uncertainty. The countries where NSPI is not cost-effective tend to be located in areas with a historically low malaria burden. In Djibouti, Lesotho, and Mauritius, the incidence of SCD is essentially zero. In Botswana, Eritrea, Ethiopia, Somalia, South Africa, and Swaziland, the incidence rate of SCD is approximately 0.01 % or less, or 10 cases out of 100,000 live births, such that the corresponding cost per DALY averted exceeds the World Health Organization (WHO) cost-effectiveness threshold, meaning that significant resources would generate relatively small improvements in population health. However, results from our scenario analysis also suggest that NSPI would be cost-effective in some of these countries if the actual incidence rate in these two populations exceeded that published rates by a factor of 2. In contrast, the results are uncertain in countries with a higher, but still relatively low annual incidence of SCD, around 0.15--0.80 %, or 150--800 cases out of 100,000 live births, such as around Central African Republic, Gambia, Guinea-Bissau, Liberia, Madagascar, Namibia, Niger, Rwanda, Sao Tome and Principe, and Zimbabwe. For these countries, the element of uncertainty is only introduced once multiple parameters are varied simultaneously in probabilistic sensitivity analyses.

In the remaining 24 countries, our model suggests NSPI would provide a very attractive return for investments in healthcare and could lead to meaningful improvements in population health. The average cost per DALY averted for these 24 countries included in the model is US\$184, which is not only cost-effective according to the WHO definition, but also compares favorably relative to other healthcare interventions in SSA. For example, the cost-effectiveness of first line antiretroviral therapy for HIV was reported at US\$620 per year of life gained in Cote d'Ivoire \[[@CR20]\], and is likely to be even higher for second-line antiretroviral therapy where annual treatment costs alone have been estimated at US\$1,037 in South Africa \[[@CR21]\]. Similarly, the cost-effectiveness of antiretroviral therapy for prevention among serodiscordant couples has been estimated at \$590 per life year saved \[[@CR22]\]. For vaccines, a review of 44 studies found that the cost per DALY averted was below US\$100 in about half of all studies reported and almost a fourth of all vaccine studies reported an estimate exceeding US\$500 \[[@CR23]\].

Our results support the WHO's call urging member countries where SCD is a public health problem to establish national health programs, operate specialized centers for SCD and facilitate access to care and treatment including NSPI \[[@CR24], [@CR25]\]. Providing access to NSPI in those states will improve childhood survival thereby contributing towards the attainment of Millennium Development Goal 4. While this analysis focuses on currently available interventions for SCD in SSA, in future, technological and medical advances may alter the clinical course of SCD as well as the cost of managing the disease in these countries.

Limitations {#Sec9}
-----------

We did not consider a third strategy where infants not screened at birth would be re-evaluated at the onset of symptoms. Screening a symptomatic subset of newborns later in life would reduce the number and cost of screening tests, but given the relatively short life expectancy in this population and the relatively poor access in the region to specialized hematology units to manage complications of SCD, it is not clear whether such an approach would be a viable strategy. However, future research could compare the cost-effectiveness of newborn screening for SSD versus delayed screening at the onset of symptoms. Also, we used mortality estimates from Tanzania across all 47 countries but the natural progression of the disease in the Tanzanian cohort may be different from other settings, especially in countries with a low malaria burden. Furthermore, elements in the prevention package in the Tanzanian cohort differed from those in our cost-assessment, e.g. we included the cost of prophylactic penicillin, which was not the standard of care in Tanzania at the time the study was conducted. In the model, we assumed that patients, or patient caretakers, would comply with the package of prophylactic interventions over their lifetime, however, imperfect compliance would reduce the health economic value of newborn screening. Last, we applied IEF screening costs as observed in Uganda to all countries in the model, but it is possible that these costs may differ in local settings.

Conclusion {#Sec10}
==========

Using IEF to screen all newborns for SCD plus administration of prophylactic interventions to affected children is cost-effective in the majority of countries in SSA.
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